If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
196
results.
Updated on
06/11/2025 [06:52:00]
Results 75 to 100 of 196
Absstract of: WO2025226879A1
A nutritional supplement includes one or more immune modulators that support a subject's cellular immunity, as well as ingredients that enhance the production and use of nitric oxide by the subject's body to better regulate the subject's cellular immunity. Such a nutritional supplement may include nano-fraction immune modulators, transfer factor, or plant transfer factor, as well as sufficient amounts of vitamin B9 and vitamin B12 to increase endothelial nitric oxide synthetase activity in a body of a subject. Methods for increasing endothelial nitric oxide synthetase activity in the body of a subject are also disclosed.
Absstract of: WO2025226878A2
Provided herein are compositions and methods to protect cargo DNA when it is loaded into lipid nanoparticles (LNPs) or similar nanocarrier systems. In certain embodiments, the compositions include a lipid nanoparticle (LNP) that includes a DNA cargo and a molecule capable of condensing and/or compacting DNA. In certain embodiments, the compositions also include a "helper molecule" that provides reduced inflammatory response and reduced DNA degradation by DNAse enzymes and autophagy/xenophagy during and after endosomal escape, upon administration.
Absstract of: WO2025226959A1
Disclosed herein are ionizable lipids, lipid nanoparticles comprising a plurality of lipids, pharmaceutical compositions and methods of use thereof (e.g., for the treatment of HIV).
Absstract of: WO2024088808A1
Provided are compositions containing microalgae extracellular vesicles (MEVs) formulated for intranasal delivery, whereby, upon intranasal administration the MEVs traffic through specific routes following intranasal administration to specific regions in the brain via the olfactory nerve and throughout the lateral olfactory tract (LOT) to interconnected brain regions. The MEVs traffic via neuronal axonal transport. The MEVs have the ability to cross-over synapses including: (i) the synapses between the olfactory sensory neurons (OSN) and the mitral/tufted neurons; (ii) the synapses between the mitral/tufted neurons and the local neurons in the various brain regions colonized by the lateral olfactory tract (LOT); and (iii) the synapses between the neurons in the brain regions colonized by the LOT and neurons from the frontal cortex, the hippocampus, the thalamus, and the hypothalamus. The compositions contain extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo for treating, detecting, diagnosing, or monitoring a disease, disorder, or condition of the brain or involving the brain, particularly providing neuronal delivery of the cargo. The compositions and methods have a variety of applications as therapeutics and diagnostics for treating, diagnosing, and monitoring a disease, disorder, or condition of the brain or involving the brain. The compositions can be used in methods and uses for treating cancers involving the brain, and can be used, for exa
Absstract of: US2025332279A1
The present invention provides a bioengineered bacteriophage-like nanoparticle, rQβ@b-3WJ, comprising a Qβ capsid and a 3WJ RNA scaffold (b-3WJ), which is a three-way junction motif integrated with (1) a Qβ phage capsid binding hairpin; (2) a light-up aptamer; and (3) a structural siRNA element (siRNA1); wherein the Qβ phage capsid binding hairpin is further integrated with a different structural siRNA element (siRNA2). Also provided is a nanoparticle, TrQβ@b-3WJ, comprising a Qβ capsid conjugated with TAT peptides and a 3WJ RNA scaffold (b-3WJ), which enhances cellular internalization for highly efficient gene silencing.
Absstract of: US2025332278A1
Methods and compositions for the treatment of atherosclerosis or cardiovascular disease are provided herein. The compositions and methods contain a nanoparticle-peptide conjugate that reduces LDL concentration in a subject, reduces reactive oxygen species in the subject, or increases cellular healing rate.
Absstract of: US2025333696A1
In certain embodiments, this disclosure provides methods to generate DNA, RNA and/or DNA-peptide nanostructures based chimeric antigen receptor (CAR) T cell (engineered T cell) for cancer immunotherapy, and compositions made by these methods.
Absstract of: US2025333401A1
In some aspects, the present disclosure provides compounds of the formulae:wherein the variables are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, the compounds or compositions of the present disclosure may be used for the treatment of diseases or disorders, such as eye diseases and peripheral arterial diseases such as hind limb ischemia.
Absstract of: WO2025226682A1
Methods and materials for effective delivery of nucleic acids (e.g., RNA molecules) to cells are provided herein. For example, methods and materials for using combinations of milk extracellular vesicles and lipid nanoparticles to deliver RNA therapies to cells are provided herein.
Absstract of: WO2024137953A2
This disclosure relates to Snu13 polypeptides and polynucleotides (e.g., mRNA) encoding the same for use in translational control of a second polynucleotide (e.g., target mRNA). mRNA therapies of the disclosure express Snu13 polypeptides, which control the translation of a target polynucleotide comprising a Snu13-binding site. Thus, the disclosure also features compositions or systems and uses thereof, comprising a first polynucleotide encoding a target molecule and comprising a Snu13-binding site and a second polynucleotide encoding a Snu13 polypeptide. The disclosure also relates to delivery agents (e.g., lipid nanoparticles) and compositions comprising the Snu13 polynucleotides (e.g., mRNAs) of the disclosure.
Absstract of: MX2025007323A
Aspects of the disclosure relate to compositions and methods for improving the stability of lipid nanoparticles (LNPs). In some embodiments, the LNPs comprise one or more active pharmaceutical ingredients (API) encapsulated therein. The disclosure is based, in part, on compositions that directly or indirectly reduce the degradation (e.g., oxidation, hydrolysis, etc.) of one or more lipids components of the lipid nanoparticle. In some embodiments, the compositions comprise a histidine buffer. The disclosure also provides methods for storing compositions contemplated herein as well as methods for improving the stability of the API.
Absstract of: MX2025007398A
The present invention provides, in part, bis-ester and amide cationic lipid compounds of Formula (I):, or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (II):, or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (III):, or a pharmaceutically acceptable salt thereof, and bis-ester and amide cationic lipid compounds of Formula (IV):, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Absstract of: WO2024133892A1
A crosslinked vesicle comprising an outer layer and an inner core, said outer layer comprising a cationic amphiphilic peptide and said inner core comprising a fluorinated compound in liquid form, wherein said cationic amphiphilic peptide is a compound of formula (I) HB - CL - HP (I), wherein HB is a fluorinated hydrophobic block, CL is a cross-linking motif, HP is a cationic hydrophilic amino acid sequence having an alpha-helix structure and comprising at least (1) positive charge and said vesicle has a zeta potential of at least (20) mV.
Absstract of: CN120475964A
There is provided a composition comprising: (a) an active ingredient; and (b) a lipid mixture comprising: (i) a cationically ionizable lipid capable of forming lipid nanoparticles; (ii) a steroid; and (iii) a negatively charged amphiphile having a hydrophilic portion and a lipophilic portion; wherein the composition is a lipid nanoparticle composition and is substantially free of a polyethylene glycol conjugated lipid wherein the polyethylene glycol (PEG) moiety of the PEG conjugated lipid has at least 5 contiguous ethylene glycol repeat units.
Absstract of: MX2025006743A
The present invention pertains to a composition comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of nucleic acids in the lipid bilayer. The present invention furthermore pertains to said composition, for use in preventing and/or treating a disease, in particular for use in preventing and/or treating cancer. The present invention furthermore pertains to a method for producing a composition comprising said nucleic acid-lipids particles.
Absstract of: WO2024134220A1
The present invention provides a cup-shaped particle comprising a first polymer and a second polymer; wherein the first polymer is a biodegradable polymer; the second polymer is a crosslinked copolymer of two or more different methacrylate monomers and at least one crosslinking agent, wherein the at least one cross-linking agent comprises one or more dimethacrylates; and wherein the cup has a cavity having an opening of at least 50 nm in size.
Absstract of: CN120569190A
The invention relates to a method for preparing stable nanoparticles and a pharmaceutical composition thereof. In addition, the nanoparticles prepared by the method have stable and controllable average particle size and particle size distribution.
Absstract of: CN120366346A
The invention belongs to the field of biological medicines, and mainly relates to a design method of a vaccine for enhancing an antigen presentation effect, which is applied to structural sequence design and preparation of nucleic acid, protein and polypeptide vaccines. According to the invention, a target antigen and ligands such as a polypeptide or a protein structural domain with an E3 ubiquitin ligase binding or recruiting function are jointly coded in the same nucleic acid sequence, so that fusion expression of an antigen protein and an E3 ubiquitin ligase ligand is realized after a nucleic acid molecule enters a cell, and then degradation of the antigen protein through a proteasome path is promoted; the number and abundance of antigen peptides with epitopes are increased, more peptide-MHC (p-MHC) compounds are formed and then presented to the cell surface, the subsequent immune response is enhanced, and the efficient tumor immunotherapy effect is achieved. The nucleic acid vaccine, the protein vaccine and the polypeptide vaccine provided by the invention have an efficient antigen presentation effect and relatively strong immunogenicity, and have a very good clinical application prospect.
Absstract of: US2025326708A1
The present disclosure relates to the field of medicine, specifically to a long-acting spleen-targeting cationic lipid compound comprising a benzene ring structure, a composition comprising the same, and a use thereof. More specifically, the present disclosure provides a compound of formula (I), or an N-oxide thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The present disclosure further provides a composition comprising the aforementioned compound and a use thereof in delivering therapeutic or prophylactic agents.
Absstract of: AU2023410864A1
The invention provides a composition, e.g., in the form of a powder, comprising chitosan particles. The invention also provides method for treating an oral condition in a patient by administering to the patient a composition of the invention to treat the oral condition. The invention further provides devices suitable for administering the composition.
Absstract of: MX2025007204A
Aspects of the present disclosure provides for improved mycobacterium tuberculosis vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl - dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Other aspects of the present disclosure provide mRNA that encodes for concatenated peptides encoding for multiple MHC-II tuberculosis epitopes, and optionally includes a second mRNA encoding for concatenated MHC-I tuberculosis epitopes.
Absstract of: WO2024137831A2
A composition of bacteriophages comprising at least one phage selected from TTS1, TTS2, TTS3, TTS4, TTS5, and TTS6, wherein the phages are optionally encapsulated; and a method for preventing or treating an infection caused by Salmonella Gallinarum by administering to a subject a therapeutically effective amount of the composition.
Absstract of: WO2024137579A2
The present disclosure relates to compositions, systems, and methods for modulating immune cell responses in a subject. In particular, the disclosure provides membrane-coated nanoparticles comprising a nanoparticle shell coated with a cell membrane obtained from an antigen presenting cell, and methods of use thereof to modulate an immune response in a sample or a subject.
Absstract of: EP4640669A1
The present invention provides a cycloalkane-based lipid compound of Formula 1 and a pharmaceutically acceptable salt thereof. The cycloalkane-based lipid compound is a compound having a form in which carbonyl-based substituents are bonded to the central structure of a cycloalkane. The cycloalkane-based lipid compound according to the present invention is used as an ionizable lipid, which is a component of a lipid nanoparticle for delivering a nucleic acid.
Nº publicación: EP4638429A1 29/10/2025
Applicant:
GREEN CROSS CORP [KR]
GREEN CROSS CORPORATION
Absstract of: MX2025006766A
The present invention relates to a novel ionizable lipid compound represented by formula (I) or a salt thereof, and lipid nanoparticles including the same. Lipid nanoparticles including a novel ionizable lipid compound according to the present invention have excellent nucleic acid encapsulation efficiency and high cell delivery efficiency of nucleic acids.
BOPI
Electronic site
